Head to Head Contrast: VivoSim Labs (NASDAQ:VIVS) versus Bruker (NASDAQ:BRKR)

Bruker (NASDAQ:BRKR) and VivoSim Labs (NASDAQ:VIVS) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their risk, valuation, dividends, analyst recommendations, profitability, institutional ownership and earnings.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Bruker and VivoSim Labs, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bruker	2	6	7	1	2.44
VivoSim Labs	1	0	0	0	1.00

Bruker presently has a consensus price target of $56.79, indicating a potential downside of 9.63%. Given Bruker’s stronger consensus rating and higher possible upside, research analysts clearly believe Bruker is more favorable than VivoSim Labs.

Volatility and Risk

Bruker has a beta of 1.29, suggesting that its share price is 29% more volatile than the S&P 500. Comparatively, VivoSim Labs has a beta of 1.4, suggesting that its share price is 40% more volatile than the S&P 500.

Earnings and Valuation

This table compares Bruker and VivoSim Labs”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bruker	$3.44 billion	2.78	-$8.60 million	($0.24)	-261.83
VivoSim Labs	$130,000.00	9.25	-$13.84 million	($5.36)	-0.06

Bruker has higher revenue and earnings than VivoSim Labs. Bruker is trading at a lower price-to-earnings ratio than VivoSim Labs, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

79.5% of Bruker shares are owned by institutional investors. Comparatively, 8.2% of VivoSim Labs shares are owned by institutional investors. 27.2% of Bruker shares are owned by company insiders. Comparatively, 2.5% of VivoSim Labs shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Bruker and VivoSim Labs’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Bruker	-0.65%	11.60%	4.25%
VivoSim Labs	-10,567.17%	-277.62%	-153.77%

Summary

Bruker beats VivoSim Labs on 12 of the 15 factors compared between the two stocks.

About Bruker

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies. It offers life science tools, and single and multiple modality systems; life science mass spectrometry; MALDI Biotyper rapid pathogen identification platform and related test kits, DNA test strips, and fluorescence-based polymerase chain reaction technology; genotype and fluorotype molecular diagnostics kits; research, analytical, and process analysis instruments and solutions; SARS-CoV 2 testing for the diagnosis of COVID-19 infection; and Fluorotyper-SARS-CoV 2 plus kits. It also provides range of portable analytical and bioanalytical detection systems, and related products; X-ray instruments; analytical tools for electron microscopes, as well as handheld, portable, and mobile X-ray fluorescence spectrometry instruments; atomic force microscopy instrumentation; non-contact nanometer resolution solution topography; and automated X-ray metrology, automated AFM defect-detection, and photomask repair and cleaning equipment. In addition, the company offers advanced optical fluorescence microscopy instruments; products and services to support the multi-omics needs of researchers in translational research, drug, and biomarker discovery; superconducting materials, such as metallic low temperature superconductors; devices and complex tools based on metallic low temperature superconductors; and non-superconducting high technology tools, such as synchrotron and beamline instrumentation. The company was incorporated in 1991 and is headquartered in Billerica, Massachusetts.

About VivoSim Labs

Organovo Holdings, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company offers ExVive human liver tissue and ExVive human kidney tissue used for predictive preclinical testing of drug compounds. It is also developing in vivo liver tissues to treat end-stage liver, life-threatening, and orphan diseases. The company was incorporated in 2007 and is headquartered in Solana Beach, California.